AbCellera Presentations & Investor Relations material

AbCellera is a Canadian biotechnology company focused on accelerating the discovery of monoclonal antibody (mAbs) therapeutics. Antibodies are molecules that are naturally produced by the immune system of humans or animals to fight off infection and disease. The unique property of antibodies is that they can specifically recognize and target diseased cells or pathogens, making them precise and highly effective drugs with low side effects for the treatment of cancer, autoimmune disorders and infections. The immune system is capable of making billions to trillions of unique antibodies, each produced by a single immune cell. Of these, only a select few are suitable for therapeutic applications. Finding these rare antibodies presents a major roadblock in the development of new therapeutics. AbCellera addresses this bottleneck by using microfluidic technology for the rapid and high-throughput analysis of antibodies directly from single cells. AbCellera is a spinoff from Dr. Carl Hansen's laboratory at the University of British Columbia in Vancouver. Founded in 2012, the company combines unique expertise and capabilities from several years of research and development on microfluidic systems and single cell analysis for the discovery of new antibody molecules for therapeutics, diagnostics and reagents applications.